Investigation announced for Investors in shares of Frequency Therapeutics, Inc.
An investigation was announced over potential securities laws violations by Frequency Therapeutics, Inc. in connection with certain financial statements.
Investors who purchased shares of Frequency Therapeutics, Inc. (NASDAQ: FREQ), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Frequency Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Woburn, MA based Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases.
On or around October 2, 2019, Frequency Therapeutics, Inc conducted its initial public offering ("IPO"), selling 6,000,000 shares of common stock priced at $14.00 per share.
On March 23, 2021, Frequency announced the topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). Frequency Therapeutics, Inc disclosed that "[t]he interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo."
Shares of Frequency Therapeutics, Inc. (NASDAQ: FREQ) declined to as low as $7.34 per share on March 30, 2021.
Those who purchased shares of Frequency Therapeutics, Inc. (NASDAQ: FREQ) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
An investigation was announced over potential securities laws violations by Frequency Therapeutics, Inc. in connection with certain financial statements.
Investors who purchased shares of Frequency Therapeutics, Inc. (NASDAQ: FREQ), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Frequency Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Woburn, MA based Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases.
On or around October 2, 2019, Frequency Therapeutics, Inc conducted its initial public offering ("IPO"), selling 6,000,000 shares of common stock priced at $14.00 per share.
On March 23, 2021, Frequency announced the topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). Frequency Therapeutics, Inc disclosed that "[t]he interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo."
Shares of Frequency Therapeutics, Inc. (NASDAQ: FREQ) declined to as low as $7.34 per share on March 30, 2021.
Those who purchased shares of Frequency Therapeutics, Inc. (NASDAQ: FREQ) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
https://www.airc.ie/advert/free-ram-national-circuit-finals-rodeo-2021-live-stream-watch-online/
https://www.airc.ie/advert/watch-free-ram-national-circuit-finals-rodeo-2021-live-stream-online/
https://www.airc.ie/advert/watch-ram-national-circuit-finals-rodeo-2021-live-free-stream-online/
https://www.airc.ie/advert/ram-national-circuit-finals-rodeo-2021-live-stream-free/
https://www.airc.ie/advert/live-tv-ram-national-circuit-finals-rodeo-2021-live-stream-free/
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.